{"componentChunkName":"component---src-templates-chapter-level-2-chapter-level-2-tsx","path":"/topics/migraine/prescribing-information/drugs-for-the-prevention-of-migraine/","result":{"pageContext":{"chapter":{"id":"b69cd3a2-8118-552d-ba35-c7db1a498617","slug":"drugs-for-the-prevention-of-migraine","fullItemName":"Drugs for the prevention of migraine","depth":2,"htmlHeader":"<!-- begin field 7e76bba0-d4d5-4ce3-984d-2a7f05ade9c5 --><h2>Drugs for the prevention of migraine</h2><!-- end field 7e76bba0-d4d5-4ce3-984d-2a7f05ade9c5 -->","summary":"","htmlStringContent":"<!-- begin item 66cf3a03-cefd-466a-9458-3f5ea0678183 --><!-- end item 66cf3a03-cefd-466a-9458-3f5ea0678183 -->","topic":{"id":"b2a19577-fc3a-5b75-948b-7c86424dba8f","topicId":"8d5c9fe8-c317-4160-9aa5-50f3a0456472","topicName":"Migraine","slug":"migraine","lastRevised":"Last revised in October 2020","chapters":[{"id":"f5de766d-b899-5cb2-978f-7194e0cbeaf4","fullItemName":"Summary","slug":"summary","subChapters":[]},{"id":"57045461-bc73-53e8-9968-49ab778a037a","fullItemName":"Have I got the right topic?","slug":"have-i-got-the-right-topic","subChapters":[]},{"id":"32406f3a-91ba-5801-9ef0-87ad7d9b3133","fullItemName":"How up-to-date is this topic?","slug":"how-up-to-date-is-this-topic","subChapters":[{"id":"52e6d993-e2b2-59c3-920f-27f34a7ec2eb","slug":"changes","fullItemName":"Changes"},{"id":"9560b149-423e-5bf5-8239-ae3f4bc97616","slug":"update","fullItemName":"Update"}]},{"id":"f6c897d2-fd52-5c54-a91b-1b366dced50e","fullItemName":"Goals and outcome measures","slug":"goals-outcome-measures","subChapters":[{"id":"058608e6-7b11-54ed-9d12-69b94ea020cf","slug":"goals","fullItemName":"Goals"},{"id":"95d8aa4b-0bce-5da9-b56a-a612d637a001","slug":"outcome-measures","fullItemName":"Outcome measures"},{"id":"f9b5443b-1c38-5f3c-be42-3e7fffa429e3","slug":"audit-criteria","fullItemName":"Audit criteria"},{"id":"d5644cb5-763c-596c-8c47-919fec89ce47","slug":"qof-indicators","fullItemName":"QOF indicators"},{"id":"92308844-16f7-5eeb-9c0a-ad97a07896ec","slug":"qipp-options-for-local-implementation","fullItemName":"QIPP - Options for local implementation"},{"id":"b97a29bb-bac7-5bc8-907c-210d887086f2","slug":"nice-quality-standards","fullItemName":"NICE quality standards"}]},{"id":"986db6f6-7568-5e6e-8095-5ce116d22307","fullItemName":"Background information","slug":"background-information","subChapters":[{"id":"b6d1719e-8f6a-509b-90d2-7d1f38e19b05","slug":"definition","fullItemName":"Definition"},{"id":"e35d9975-5859-5454-9539-fab1a8ca6a43","slug":"causes","fullItemName":"Causes"},{"id":"3d8350c0-8bc5-5793-a577-411bc703d36f","slug":"prevalence","fullItemName":"Prevalence"},{"id":"eea7fb2e-ce45-5fa7-9ff5-5399f8305dd7","slug":"prognosis","fullItemName":"Prognosis"},{"id":"ad3ec7a1-a418-5232-b554-b202784e3f46","slug":"complications","fullItemName":"Complications"}]},{"id":"23b2a2ec-5694-51eb-97af-5e80f8d0b792","fullItemName":"Diagnosis","slug":"diagnosis","subChapters":[{"id":"86e96919-af81-53dc-805a-36533fa27637","slug":"diagnosis","fullItemName":"Diagnosis"},{"id":"1b00b35a-f7c5-5dc3-bd7d-6e72a973af14","slug":"assessment","fullItemName":"Assessment"},{"id":"33c2a435-70da-50e9-b336-2d81b68f99c9","slug":"differential-diagnosis","fullItemName":"Differential diagnosis"}]},{"id":"1ece6bbf-1986-5392-be1d-427e9603f26a","fullItemName":"Management","slug":"management","subChapters":[{"id":"eb14162e-c87a-5ca7-8eda-4acb5c336298","slug":"adults","fullItemName":"Scenario: Adults"},{"id":"3bced75d-3a79-536f-976d-875a40bf1a8d","slug":"young-people-aged-12-17-years","fullItemName":"Scenario: Young people aged 12-17 years"},{"id":"604f5c24-3920-5626-893b-9c27575decc6","slug":"pregnant-or-breastfeeding-women","fullItemName":"Scenario: Pregnant or breastfeeding women"}]},{"id":"8e2844f3-6843-5776-a5a1-59b0cabc5b93","fullItemName":"Prescribing information","slug":"prescribing-information","subChapters":[{"id":"d1661673-77b9-587b-94ce-e5b6ff9de8c5","slug":"drugs-for-acute-migraine","fullItemName":"Drugs for acute migraine"},{"id":"b69cd3a2-8118-552d-ba35-c7db1a498617","slug":"drugs-for-the-prevention-of-migraine","fullItemName":"Drugs for the prevention of migraine"}]},{"id":"daf55050-4154-5b6d-b8ab-0f86775d1038","fullItemName":"Supporting evidence","slug":"supporting-evidence","subChapters":[]},{"id":"0fbeb3e2-26df-5d63-a045-8af31aed07ef","fullItemName":"How this topic was developed","slug":"how-this-topic-was-developed","subChapters":[{"id":"88a22f7c-7eb4-5b57-a406-ab204723d6c0","slug":"search-strategy","fullItemName":"Search strategy"},{"id":"596ed3f2-0ac4-5fd9-9046-b304311543ee","slug":"stakeholder-engagement","fullItemName":"Stakeholder engagement"},{"id":"c4597510-7ec3-5f98-b5a5-3ef55cd51b5e","slug":"evidence-exclusion-criteria","fullItemName":"Evidence exclusion criteria"},{"id":"79a12dcb-038c-5fd4-a311-648c3ee61102","slug":"organizational-behavioural-financial-barriers","fullItemName":"Organizational, behavioural and financial barriers"},{"id":"41030681-d726-58c4-b509-29748e404597","slug":"declarations-of-interest","fullItemName":"Declarations of interest"}]},{"id":"9a8a7e48-db76-50eb-a585-96fe1b4a5977","fullItemName":"References","slug":"references","subChapters":[]}]},"parentChapter":{"id":"8e2844f3-6843-5776-a5a1-59b0cabc5b93","slug":"prescribing-information","fullItemName":"Prescribing information"},"subChapters":[{"id":"a78282f3-e583-5d39-bd5c-04987db0afb4","slug":"propranolol","fullItemName":"Propranolol","depth":3,"htmlHeader":"<!-- begin field 91bfc624-b54e-44c9-9200-8919f781596b --><h3>Propranolol</h3><!-- end field 91bfc624-b54e-44c9-9200-8919f781596b -->","summary":"","htmlStringContent":"<!-- begin item 1fd78f52-9795-45a1-9b73-60c3dc87105b --><!-- begin field d9314d1e-6b48-4108-8edf-46ac23d46424 --><h4>Cautions and contraindications</h4><ul><li><strong>Do not prescribe propranolol to people with:</strong><ul><li>Asthma or obstructive airways disease — may precipitate bronchospasm that is unresponsive to beta2-agonists.</li><li>Cardiovascular disorders such as cardiogenic shock; hypotension; marked bradycardia; heart block; angina, peripheral vascular disease and heart failure.</li><li>Phaeochromocytoma.</li></ul></li><li><strong>Prescribe propranolol with caution in people with:</strong><ul><li>Diabetes — may alter blood glucose levels and response to hypoglycaemia.</li><li>Myasthenia gravis</li><li>Hepatic and renal impairment.</li><li>History of anaphylaxis.</li><li>Psoriasis.</li></ul></li></ul><h4>Adverse effects</h4><ul><li><strong>Adverse effects include:</strong><ul><li>Metabolic and endocrine disorders — may cause hypoglycaemia (even in nondiabetics).</li><li>Nervous system disorders — dizziness, headache, paraesthesia, confusion and rarely myasthenia gravis like syndrome.</li><li>Psychiatric disorders — sleep disturbances, nightmares, and depression.</li><li>Eye disorders — dry eye.</li><li>Cardiovascular disorders — bradycardia, heart failure, peripheral vascular disease, hypotension, cold extremities, and Raynaud's syndrome.</li><li>Respiratory disorders — bronchospasm and dyspnoea.</li><li>Gastrointestinal disorders — diarrhoea, nausea, vomiting, constipation and dry mouth.</li><li>Skin disorders — alopecia, exacerbation of psoriasis, and rash.</li><li>Genitourinary disorders — sexual dysfunction.</li><li>General disorders — fatigue and lassitude.</li></ul></li></ul><h4>Drug interactions</h4><ul><li>Calcium channel blockers and anti-arrhythmic drugs — avoid, may result in severe hypotension, bradycardia and cardiac failure.</li><li>Anti-coagulants — may increase plasma concentration of warfarin.</li><li>Antidiabetic drugs — modifies response to hypoglycaemia.</li><li>Antihypertensive drugs — may result in an enhanced hypotensive effect.</li><li>Methyldopa and levodopa — may result in an enhanced hypotensive effect.</li><li>Ergotamine or related compounds — vasospastic reactions have been reported.</li></ul><h4>Pregnancy and breastfeeding</h4><ul><li><strong>Pregnancy</strong><ul><li>Avoid — beta-blockers may cause intra-uterine growth restriction, neonatal hypoglycaemia, and bradycardia.</li><li>Manufacturer advises that propranolol should not be given in pregnancy unless essential.</li></ul></li><li><strong>Breast feeding</strong><ul><li>Amount present in breast milk likely too small to affect infants however there is a risk of possible toxicity due to beta-blockade.</li><li>Manufacturer advises that propranolol should not be given in lactation unless essential.</li></ul></li></ul><p>[<a class=\"bibliography-reference internal-reference\" href=\"/topics/migraine/references/\">Becker, 2015</a>]  [<a class=\"bibliography-reference internal-reference\" href=\"/topics/migraine/references/\">Becker, 2015</a>; <a class=\"bibliography-reference internal-reference\" href=\"/topics/migraine/references/\">ABPI, 2019d</a>; <a class=\"bibliography-reference internal-reference\" href=\"/topics/migraine/references/\">Joint Formulary Committee, 2019</a>]</p><!-- end field d9314d1e-6b48-4108-8edf-46ac23d46424 --><!-- end item 1fd78f52-9795-45a1-9b73-60c3dc87105b -->","subChapters":[]},{"id":"e23dc33d-ddf8-5a58-80b6-dde49199221c","slug":"topiramate","fullItemName":"Topiramate","depth":3,"htmlHeader":"<!-- begin field a77ef474-a86b-4ca8-8318-df81dbff1ade --><h3>Topiramate</h3><!-- end field a77ef474-a86b-4ca8-8318-df81dbff1ade -->","summary":"","htmlStringContent":"<!-- begin item a0c5653c-dc13-42eb-986d-986227bb7cfe --><!-- begin field 683bf63a-2cc6-47f0-a79b-f9f0aa495ea1 --><ul><li>Topiramate should be initiated at a low dose and titrated slowly.</li><li>Topiramate is contraindicated in pregnancy.<ul><li>Highly effective contraception is required prior to initiation — topiramate can impair the effectiveness of some hormonal contraceptives.</li><li>Women should be advised to seek further advice on migraine prophylaxis if planning a pregnancy.</li></ul></li><li>Use in Scotland is restricted to people who have not responded to at least one other prophylactic agent.</li></ul><h4>Cautions and contraindications</h4><ul><li><strong>Do not prescribe topiramate in:</strong><ul><li>Pregnancy — increased risk of fetal malformations.</li><li>Children.</li><li>Acute porphyria.</li></ul></li><li><strong>Topiramate should be prescribed with caution in:</strong><ul><li>Women of child-bearing age — a highly effective method of contraception is required as topiramate can impair the effectiveness of hormonal contraceptives. Pregnancy test advised before initiation.</li><li>Breastfeeding — adverse effects reported in breastfed newborns/infants of treated mothers (seek specialist advice).</li><li>People at risk of metabolic acidosis.</li><li>People at risk of nephrolithiasis.</li><li>Hepatic and renal impairment.</li></ul></li></ul><h4>Adverse effects</h4><ul><li><strong>Adverse effects include:</strong><ul><li>Nervous system disorders — cognitive impairment, confusion, dizziness, drowsiness, seizures, tremor, abnormal coordination, and abnormal sensation.</li><li>Psychiatric disorders — anxiety, depression, suicidal ideation/behaviour, mood swings and sleep disorders.</li><li>Respiratory disorders — cough, and dyspnoea.</li><li>Gastrointestinal disorders — gastrointestinal discomfort, constipation, diarrhoea, vomiting, dry mouth, nausea, anorexia and altered taste.</li><li>Renal disorders — nephrolithiasis.</li><li>Skin disorders — alopecia, decreased sweating, pruritus, and rash.</li><li>Eye disorders — topiramate has been associated with acute myopia with secondary angle closure glaucoma and uveitis.</li><li>Metabolic disorders — metabolic acidosis.<ul><li>Hyperammonemia with or without encephalopathy has been reported with topiramate treatment. This risk is dose-related.</li><li>In patients who develop unexplained lethargy or changes in mental status associated with topiramate monotherapy or adjunctive therapy, it is recommended to consider hyperammonemic encephalopathy and to measure serum ammonia levels.</li><li>Hyperammonemia has been reported more frequently when topiramate is used concomitantly with valproic acid.</li></ul></li><li>Musculoskeletal disorders — joint disorders, and muscle weakness.</li><li>Haematological disorders — anaemia.</li><li>Malaise.</li></ul></li></ul><h4>Drug interactions</h4><ul><li>Oral contraceptives — decreases the efficacy of combined hormonal contraceptives.</li><li>Carbamazepine, phenytoin and valproate — increased risk of toxicity.</li><li>Warfarin — may lead to decreased prothrombin time/international normalized ratio (INR).</li></ul><h4>Pregnancy and breastfeeding</h4><ul><li><strong>Topiramate is contraindicated in pregnancy</strong><ul><li>Women should be fully informed of the risks related to the use of topiramate during pregnancy (major congenital malformations).</li><li>A highly effective contraceptive method is advised in women of child-bearing potential — a pregnancy test should be performed before initiation of treatment.</li></ul></li><li><strong>Topiramate should be avoided in breastfeeding</strong><ul><li>Topiramate is present in breast milk — adverse effects reported in breastfed newborns/infants of treated mothers.</li><li>Manufacturer recommends that decision to suspend breastfeeding or to discontinue/ abstain from topiramate therapy must be made taking into account the benefit of breastfeeding for the child and the benefit of topiramate therapy for the woman.</li></ul></li></ul><p>[<a class=\"bibliography-reference internal-reference\" href=\"/topics/migraine/references/\">NICE, 2012 (updated 2015)</a>; <a class=\"bibliography-reference internal-reference\" href=\"/topics/migraine/references/\">Schwedt, 2014</a>; <a class=\"bibliography-reference internal-reference\" href=\"/topics/migraine/references/\">Becker, 2015</a>; <a class=\"bibliography-reference internal-reference\" href=\"/topics/migraine/references/\">SIGN, 2018</a>; <a class=\"bibliography-reference internal-reference\" href=\"/topics/migraine/references/\">ABPI, 2019e</a>; <a class=\"bibliography-reference internal-reference\" href=\"/topics/migraine/references/\">Joint Formulary Committee, 2019</a>; <a class=\"bibliography-reference internal-reference\" href=\"/topics/migraine/references/\">ABPI, 2020</a>]</p><!-- end field 683bf63a-2cc6-47f0-a79b-f9f0aa495ea1 --><!-- end item a0c5653c-dc13-42eb-986d-986227bb7cfe -->","subChapters":[]},{"id":"7a32acd4-1e97-5bf1-8a61-7e751aac1575","slug":"amitriptyline","fullItemName":"Amitriptyline","depth":3,"htmlHeader":"<!-- begin field ecdaee1e-742f-4abe-8dc0-6bf994c51888 --><h3>Amitriptyline</h3><!-- end field ecdaee1e-742f-4abe-8dc0-6bf994c51888 -->","summary":"","htmlStringContent":"<!-- begin item 219e45c4-ac77-470e-8765-7882b99f7f01 --><!-- begin field 8149e91b-c0ab-4123-8b31-f53909f5e879 --><ul><li>For detailed prescribing information on amitriptyline, see the CKS topic on <a class=\"topic-reference external-reference\" href=\"/topics/neuropathic-pain-drug-treatment/\">Neuropathic pain - drug treatment</a>.<ul><li>The dose range specified for amitriptyline for the indication of migraine prophylaxis in adults in the BNF and the Summary of Product Characteristics is 25-75 mg at night.</li><li>SIGN guidance states that amitriptyline (25–150 mg at night, target dose 30–50 mg) can be considered as a prophylactic treatment for patients with episodic or chronic migraine.</li><li>NICE guidance states that amitriptyline can be considered for the prophylactic treatment of migraine according to the person's preference, comorbidities and risk of adverse events — no dose range is specified.</li></ul></li></ul><p>[<a class=\"bibliography-reference internal-reference\" href=\"/topics/migraine/references/\">NICE, 2012 (updated 2015)</a>; <a class=\"bibliography-reference internal-reference\" href=\"/topics/migraine/references/\">ABPI, 2017</a>; <a class=\"bibliography-reference internal-reference\" href=\"/topics/migraine/references/\">SIGN, 2018</a>; <a class=\"bibliography-reference internal-reference\" href=\"/topics/migraine/references/\">Joint Formulary Committee, 2019</a>]</p><!-- end field 8149e91b-c0ab-4123-8b31-f53909f5e879 --><!-- end item 219e45c4-ac77-470e-8765-7882b99f7f01 -->","subChapters":[]}]}}},"staticQueryHashes":["3666801979"]}